Literature DB >> 3138975

Purification of anthrax-toxin components by high-performance anion-exchange, gel-filtration and hydrophobic-interaction chromatography.

C P Quinn1, C C Shone, P C Turnbull, J Melling.   

Abstract

A procedure has been developed for purification of the tripartite anthrax-toxin components. This involves sequential high-performance anion-exchange, gel-filtration and hydrophobic-interaction chromatography. From an initial culture volume of 15 litres, typical yields of 8 mg of protective antigen, 13 mg of lethal factor and 7 mg of oedema factor are produced to higher degrees of purity than have previously been achieved by conventional chromatographic techniques.

Entities:  

Mesh：

Substances：

Year:  1988        PMID： 3138975      PMCID： PMC1149211          DOI： 10.1042/bj2520753

Source DB:  PubMed          Journal:  Biochem J        ISSN： 0264-6021            Impact factor:   3.857


  13 in total

1.  Polyglutamic acid from Bacillus anthracis grown in vivo; structure and aggressin activity.

Authors:  H T ZWARTOUW; H SMITH
Journal:  Biochem J       Date:  1956-07       Impact factor: 3.857

2.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

3.  Proposed structure for brain adenylate cyclase purified using blue dextran-Sepharose chromatography.

Authors:  E Stellwagen; B Baker
Journal:  Nature       Date:  1976-06-24       Impact factor: 49.962

4.  Affinity chromatography on immobilized dyes.

Authors:  C R Lowe; J C Pearson
Journal:  Methods Enzymol       Date:  1984       Impact factor: 1.600

5.  Comparison of enzyme-linked immunosorbent and indirect hemagglutination assays for determining anthrax antibodies.

Authors:  A Johnson-Winegar
Journal:  J Clin Microbiol       Date:  1984-09       Impact factor: 5.948

6.  Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin.

Authors:  J W Ezzell; B E Ivins; S H Leppla
Journal:  Infect Immun       Date:  1984-09       Impact factor: 3.441

7.  Bacillus anthracis calmodulin-dependent adenylate cyclase: chemical and enzymatic properties and interactions with eucaryotic cells.

Authors:  S H Leppla
Journal:  Adv Cyclic Nucleotide Protein Phosphorylation Res       Date:  1984

8.  Elaboration of Bacillus anthracis antigens in a new, defined culture medium.

Authors:  J D Ristroph; B E Ivins
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

9.  Preparation and characterisation of homogeneous neurotoxin type A from Clostridium botulinum. Its inhibitory action on neuronal release of acetylcholine in the absence and presence of beta-bungarotoxin.

Authors:  C K Tse; J O Dolly; P Hambleton; D Wray; J Melling
Journal:  Eur J Biochem       Date:  1982-03-01

10.  Effects of anthrax toxin components on human neutrophils.

Authors:  J O'Brien; A Friedlander; T Dreier; J Ezzell; S Leppla
Journal:  Infect Immun       Date:  1985-01       Impact factor: 3.441
View more
  16 in total

1.  Search for correlates of protective immunity conferred by anthrax vaccine.

Authors:  S Reuveny; M D White; Y Y Adar; Y Kafri; Z Altboum; Y Gozes; D Kobiler; A Shafferman; B Velan
Journal:  Infect Immun       Date:  2001-05       Impact factor: 3.441

2.  Serology and anthrax in humans, livestock and Etosha National Park wildlife.

Authors:  P C Turnbull; M Doganay; P M Lindeque; B Aygen; J McLaughlin
Journal:  Epidemiol Infect       Date:  1992-04       Impact factor: 2.451

3.  Anthrax toxin: channel-forming activity of protective antigen in planar phospholipid bilayers.

Authors:  R O Blaustein; T M Koehler; R J Collier; A Finkelstein
Journal:  Proc Natl Acad Sci U S A       Date:  1989-04       Impact factor: 11.205

4.  Purification of anthrax edema factor from Escherichia coli and identification of residues required for binding to anthrax protective antigen.

Authors:  P Kumar; N Ahuja; R Bhatnagar
Journal:  Infect Immun       Date:  2001-10       Impact factor: 3.441

5.  Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors.

Authors:  N M Cirino; D Sblattero; D Allen; S R Peterson; J D Marks; P J Jackson; A Bradbury; B E Lehnert
Journal:  Infect Immun       Date:  1999-06       Impact factor: 3.441

6.  Anthrax lethal and edema toxins fail to directly impair human platelet function.

Authors:  Kassidy M Chauncey; Sarah E Szarowicz; Gurjit S Sidhu; Russell L During; Frederick S Southwick
Journal:  J Infect Dis       Date:  2011-12-07       Impact factor: 5.226

7.  Attenuated nontoxinogenic and nonencapsulated recombinant Bacillus anthracis spore vaccines protect against anthrax.

Authors:  S Cohen; I Mendelson; Z Altboum; D Kobiler; E Elhanany; T Bino; M Leitner; I Inbar; H Rosenberg; Y Gozes; R Barak; M Fisher; C Kronman; B Velan; A Shafferman
Journal:  Infect Immun       Date:  2000-08       Impact factor: 3.441

8.  Antibodies to anthrax toxin in humans and guinea pigs and their relevance to protective immunity.

Authors:  P C Turnbull; S H Leppla; M G Broster; C P Quinn; J Melling
Journal:  Med Microbiol Immunol       Date:  1988       Impact factor: 3.402

9.  Use of a promoter trap system in Bacillus anthracis and Bacillus subtilis for the development of recombinant protective antigen-based vaccines.

Authors:  O Gat; I Inbar; R Aloni-Grinstein; E Zahavy; C Kronman; I Mendelson; S Cohen; B Velan; A Shafferman
Journal:  Infect Immun       Date:  2003-02       Impact factor: 3.441

10.  Bacillus anthracis edema toxin impairs neutrophil actin-based motility.

Authors:  Sarah E Szarowicz; Russell L During; Wei Li; Conrad P Quinn; Wei-Jen Tang; Frederick S Southwick
Journal:  Infect Immun       Date:  2009-04-06       Impact factor: 3.441
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.